Proficio Capital Partners LLC Acquires New Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Proficio Capital Partners LLC bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 25,583 shares of the biotechnology company’s stock, valued at approximately $192,000.

A number of other institutional investors have also added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. grew its stake in shares of BioCryst Pharmaceuticals by 4.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock valued at $14,890,000 after buying an additional 91,998 shares during the last quarter. Los Angeles Capital Management LLC grew its position in BioCryst Pharmaceuticals by 16.9% in the 4th quarter. Los Angeles Capital Management LLC now owns 101,188 shares of the biotechnology company’s stock worth $761,000 after purchasing an additional 14,655 shares during the period. Ieq Capital LLC purchased a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth approximately $221,000. Venturi Wealth Management LLC purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $46,000. Finally, Rhumbline Advisers raised its holdings in BioCryst Pharmaceuticals by 1.8% during the fourth quarter. Rhumbline Advisers now owns 309,132 shares of the biotechnology company’s stock valued at $2,325,000 after acquiring an additional 5,615 shares during the period. 85.88% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $11.00 target price (up from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. JMP Securities reiterated a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Evercore ISI increased their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Finally, Wedbush started coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an “outperform” rating and a $15.00 target price for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $15.57.

BioCryst Pharmaceuticals Stock Up 0.4 %

Shares of NASDAQ BCRX opened at $7.83 on Friday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $9.50. The firm has a market cap of $1.64 billion, a PE ratio of -12.84 and a beta of 1.85. The business has a fifty day simple moving average of $8.17 and a two-hundred day simple moving average of $7.82.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same quarter last year, the firm posted $0.28 EPS. BioCryst Pharmaceuticals’s quarterly revenue was up 40.8% compared to the same quarter last year. On average, research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.